- Home
- HURN vs KNSA Comparison
HURN vs KNSA Comparison
Compare HURN & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HURN
- KNSA
- Stock Information
- Founded
- HURN 2002
- KNSA 2015
- Country
- HURN United States
- KNSA United Kingdom
- Employees
- HURN N/A
- KNSA N/A
- Industry
- HURN Professional Services
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- HURN Consumer Discretionary
- KNSA Health Care
- Exchange
- HURN Nasdaq
- KNSA Nasdaq
- Market Cap
- HURN 2.6B
- KNSA 2.6B
- IPO Year
- HURN 2004
- KNSA 2018
- Fundamental
- Price
- HURN $162.00
- KNSA $38.01
- Analyst Decision
- HURN Strong Buy
- KNSA Strong Buy
- Analyst Count
- HURN 4
- KNSA 7
- Target Price
- HURN $171.50
- KNSA $46.86
- AVG Volume (30 Days)
- HURN 155.2K
- KNSA 454.2K
- Earning Date
- HURN 10-28-2025
- KNSA 10-28-2025
- Dividend Yield
- HURN N/A
- KNSA N/A
- EPS Growth
- HURN 37.96
- KNSA N/A
- EPS
- HURN 5.74
- KNSA 0.47
- Revenue
- HURN $1,556,665,000.00
- KNSA $597,973,000.00
- Revenue This Year
- HURN $13.32
- KNSA $53.93
- Revenue Next Year
- HURN $8.31
- KNSA $25.06
- P/E Ratio
- HURN $26.56
- KNSA $84.46
- Revenue Growth
- HURN 9.24
- KNSA 55.68
- 52 Week Low
- HURN $103.24
- KNSA $17.82
- 52 Week High
- HURN $155.38
- KNSA $42.05
- Technical
- Relative Strength Index (RSI)
- HURN 73.41
- KNSA 50.20
- Support Level
- HURN $150.49
- KNSA $35.53
- Resistance Level
- HURN $155.30
- KNSA $41.28
- Average True Range (ATR)
- HURN 3.54
- KNSA 1.50
- MACD
- HURN 0.50
- KNSA -0.14
- Stochastic Oscillator
- HURN 100.00
- KNSA 43.13
About HURN Huron Consulting Group Inc.
Huron Consulting Group Inc is a professional services firm. The company provides expertise in technology, operations, advisory services, & analytics through three operating segments namely Healthcare, Education, and Commercial. Healthcare segment helps the firms to transform and innovate the delivery model to focus on patient wellness by improving quality outcomes, minimizing care variation and fundamentally improving patient and population health, Education segment provides management consulting and technology solutions, and Commercial segment is focused on serving industries and organizations facing disruption and regulatory change. It generates a majority of its revenue from the Healthcare Segment.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.